Sanofi plans to invest in ‘center of excellence’ that focuses on mRNA vaccines

FRANCE- The French pharmaceutical giant Sanofi has announced its plan to invest US$475.4m into a new facility focused on solely on the development and delivery of next-generation mRNA-based vaccines. The new mRNA ‘center of excellence’ is expected to employ approximately 400 new staff members in a bid to integrate end-to-end mRNA vaccine capabilities. This investment will see Sanofi bringing together dedicated research & development, digital and chemistry, manufacturing and controls (CMC) teams, working across sites based in the US and France. “During the COVID-19 pandemic, mRNA technologies demonstrated potential to…

Read More